Maria Sjlund, MSc; Karin Wreiber, MSc; Dan I. Andersson, PhD; Martin J. Blaser, MD; Lars Engstrand, MD
Acknowledgments: The authors thank Lena Zimmergren for coordinating the collection of samples and Lena Eriksson and Kristina Schnmeyr for excellent technical assistance.
Grant Support: By the AFA Health Research Foundation, Stockholm, Sweden, and by the National Institutes of Health (RO1GM63270).
Potential Financial Conflicts of Interest: None disclosed.
Requests for Single Reprints: Lars Engstrand, MD, Department of Bacteriology, Swedish Institute for Infectious Disease Control, SE-171 82 Solna, Sweden; e-mail, firstname.lastname@example.org.
Current Author Addresses: Ms. Sjlund: Department of Medical Sciences, Clinical Bacteriology, University Hospital Uppsala, Box 552, SE-751 22 Uppsala, Sweden.
Ms. Wreiber and Drs. Andersson and Engstrand: Department of Bacteriology, Swedish Institute for Infectious Disease Control, SE-171 82 Solna, Sweden.
Dr. Blaser: Departments of Medicine and Microbiology, New York University School of Medicine, New York, NY 10016.
Author Contributions: Conception and design: M. Sjlund, L. Engstrand.
Analysis and interpretation of the data: M. Sjlund, D.I. Andersson, M.J. Blaser, L. Engstrand.
Drafting of the article: M. Sjlund, D.I. Andersson, M.J. Blaser, L. Engstrand.
Critical revision of the article for important intellectual content: M. Sjlund, D.I. Andersson, M.J. Blaser, L. Engstrand.
Final approval of the article: M. Sjlund, K. Wreiber, D.I. Andersson, M.J. Blaser, L. Engstrand.
Provision of study materials or patients: K. Wreiber.
Obtaining of funding: L. Engstrand.
Administrative, technical, or logistic support: K. Wreiber, L. Engstrand.
Collection and assembly of data: K. Wreiber, L. Engstrand.
Antibiotic treatment selects for resistance not only in the pathogen to which it is directed but also in the indigenous microflora.
To determine whether a widely used regimen (clarithromycin, metronidazole, and omeprazole) for Helicobacter pylori eradication affects resistance development in enterococci.
Endoscopy units at 3 community hospitals in Sweden.
5 consecutive dyspeptic patients who were colonized with H. pylori, had endoscopy-confirmed duodenal ulcer, and received antibiotic treatment, and 5 consecutive controls with dyspepsia but no ulcer who did not receive treatment.
Fecal samples were obtained from patients and controls before, immediately after, 1 year after, and 3 years after treatment. From each patient and sample, enterococci were isolated and analyzed for DNA fingerprint, clarithromycin susceptibility, and presence of the erm(B) gene.
In treated patients, all enterococci isolated immediately after treatment showed high-level clarithromycin resistance due to erm(B). In 3 patients, resistant enterococci persisted for 1 to 3 years after treatment. No resistance developed among controls.
A common H. pylori treatment selects for highly resistant enterococci that can persist for at least 3 years without further selection.
Learn more about subscription options.
Register Now for a free account.
Sjlund M, Wreiber K, Andersson DI, Blaser MJ, Engstrand L. Long-Term Persistence of Resistant Enterococcus Species after Antibiotics To Eradicate Helicobacter pylori. Ann Intern Med. 2003;139:483-487. doi: 10.7326/0003-4819-139-6-200309160-00011
Download citation file:
Published: Ann Intern Med. 2003;139(6):483-487.
Gastroenterology/Hepatology, H. Pylori, Infectious Disease, Peptic Disease.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only